Company / R&D Expense
Collegium Pharmaceutical, Inc. R&D Expense History
FY2016-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
-
FY2024
5-year range
$0 / $9.5M
FY2020-FY2024
Trend
-
vs FY2023
Sector context
#211 of 210
Health Care
What the data says
Declined from $4M to $0 over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 0% in Health CareTop 100% of 210
▼
Key checks
Key Insights
- Peak r&d expense was recorded in FY2016.
Company context
Key Data Points
- Altman Z-Score 0.96 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | $0 | - |
| FY2023 | $0 | -100.0% |
| FY2022 | $4.0M | -57.9% |
| FY2021 | $9.5M | -3.3% |
| FY2020 | $9.8M | -5.5% |
| FY2019 | $10.3M | +19.4% |
| FY2018 | $8.7M | +8.6% |
| FY2017 | $8.0M | -46.6% |
| FY2016 | $14.9M | +87.4% |
As of FY2024 · SEC 10-K · Updated Jul 2, 2026